Cargando…
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Blocking the MDM2/X–P53 protein–protein interaction has been widely recognized as an attractive therapeutic strategy for the treatment of cancers. Numerous small-molecule MDM2 inhibitors have been reported since the release of the structure of the MDM2–P53 interaction in 1996, SAR405838, NVP-CGM097,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452049/ https://www.ncbi.nlm.nih.gov/pubmed/32874827 http://dx.doi.org/10.1016/j.apsb.2020.01.003 |